STROBE Statement—Checklist of items that should be included in reports of *case-control studies*

	Item No	Recommendation	Page No
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	Abstract (p. 4)
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	Abstract (p. 4)
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	5-6
Objectives	3	State specific objectives, including any prespecified hypotheses	6
Methods			
Study design	4	Present key elements of study design early in the paper	6-9
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	6-7 / Suppl. Table S3 (p. 5-13) / Suppl Fig. S1(p. 19)
Participants	6	(a) Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls	6 / Suppl. Table S3 (p. 5-13) / SM (p. 1-2)
		(b) For matched studies, give matching criteria and the number of controls per case	NA
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	7-9 / Suppl. Table S3 (p. 5-13)
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	6-9 / Suppl. Tables S3 & S4 (p. 5-17) / SM (p. 2)
Bias	9	Describe any efforts to address potential sources of bias	8-9 / SM (p. 1-3)
Study size	10	Explain how the study size was arrived at	6 / SM (p.1-2)
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	8-9
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	7-9
		(b) Describe any methods used to examine subgroups and interactions	8-9
		(c) Explain how missing data were addressed	SM (p. 1)
		(d) If applicable, explain how matching of cases and controls was addressed	NA

		(\underline{e}) Describe any sensitivity analyses	9, 11
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	NA
		(b) Give reasons for non-participation at each stage	NA
		(c) Consider use of a flow diagram	NA
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	10-11; Suppl. Tables S1 & S2 (p. 3-4)
		(b) Indicate number of participants with missing data for each variable of interest	NA
Outcome data	15*	Report numbers in each exposure category, or summary measures of exposure	6, 11-13; Suppl. Tables S1 and& S2 (p. 3-4)

Main results		16 (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear	11-13
		which confounders were adjusted for and why they were included	
		(b) Report category boundaries when continuous variables were categorized	NA
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	NA
Other analyses			
Discussion			
Key results	18	Summarise key results with reference to study objectives	14
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	16-17
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	14-17
Generalisability	21	Discuss the generalisability (external validity) of the study results	14, 16-17
Other informati	on		
Funding	22	Give the source of funding and the role of the funders for the present study and, if	18-21
		applicable, for the original study on which the present article is based	10 21

^{*}Give information separately for cases and controls.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at http://www.strobe-statement.org.